

Ainos, Inc.

WKN: A41AZJ | ISIN: US00902F4028 | Bloomberg Symbol: AIMD:US AI Nose Enters the Emergency Room: The First Live Hospital Deployment

Published: 06/04/2026

For the first time, AI Nose is breathing the air of a hospital emergency department. On 1 June, Ainos announced an IRB-approved research program with National Taiwan University Hospital (NTUH), one of Asia's leading academic medical centres, to run its Smell AI platform in a live ER, with units placed across the waiting, treatment and observation areas. There, in one of the busiest and least predictable rooms in any hospital, the system reads the air and turns it into machine-readable "Smell ID" data, with a clear job to do: serve as an early-warning system for emergency-department overcrowding and respiratory-infection risk.

The reason this lands as more than another pilot is timing. **In our May update**, among the items we put under watch was whether the hospital lane would grow beyond building infrastructure into something deeper. That step is now here, and it arrives under the name of a top-tier academic institution, in the clinical heart of the hospital rather than its plant room.

The substance is concrete and verifiable:

- **A defined study with a measurable output.** Positioning as an early-warning system for ER overcrowding and respiratory-infection risk using an AI electronic nose, it runs roughly six months and is designed to generate more than 2,500 hours of emergency-department environmental data.
- **A targeted deployment.** Physical units sit across the ER's waiting, treatment and observation zones, reading scent and air-pattern signals tied to crowd density, patient flow and infection-related change.
- **A deliberately clean data boundary.** No diagnosis, no images, no audio, no personally identifiable information, environmental-level analysis only. That design is what makes a non-invasive study approachable inside a working ER.
- **A purpose beyond the study itself.** The ER serves as a demanding, real-world environment that feeds the Smell Language Model with new scent data, the kind of operating experience the platform compounds over time.

Stock price* USD 2.38

*last NASDAQ closing price



Source: NASDAQ

| Change | FY2024 | 2025A | Q1 / 2026A |
|--------|--------|-------|------------|
| Sales | 0.0 | 0.0 | 0.0 |
| EBIT | 0.0 | 0.0 | 0.0 |
| Cash | 0.0 | 0.0 | 0.0 |

Stock Basic Data

| | |
|-------------------------------|--------|
| Number of Shares (in million) | 8.52 |
| Free Float (in %) | 36.90% |
| Market Cap (in million USD) | 19.14 |
| Trading Volume (Ø) | 87,060 |
| High (USD, 52 weeks) | 4.50 |
| Low (USD, 52 weeks) | 1.26 |

Shareholder Structure

| | |
|-----------------------------------|--------|
| TCNT | 53.55% |
| Individual Insiders | 9.55% |
| Institutional Holders | 1.89% |
| Free float and other shareholders | 35.01% |

Corporate Calendar

| | |
|-----------------|-----------------------------|
| Q2 2026 results | Expected by mid-August 2026 |
|-----------------|-----------------------------|

Analyst(s)

Dr. Vaseghi, Javad
Lead Equity Analyst, CEO
Roghani, Emad
Analyst

vaseghi@vasro.de
+49 (0)69 90 28 39 81

Contact

VASRO GmbH
Am Hauptbahnhof 16
60329 Frankfurt am Main
Germany

+49 (0)69 90 28 39 81
www.vasro.de

| FY End: 31.12.; in USD m | 2021A | 2022A | 2023A | 2024A | 2025A | Q1 / 2026A |
|--------------------------------|---------|---------|---------|---------|---------|------------|
| Sales | 0.590 | 3.520 | 0.122 | 0.0207 | 0.1242 | 0.0002 |
| EBIT | (3.87) | (13.98) | (13.20) | (13.84) | (13.99) | (2.28) |
| Net Result | (3.89) | (14.01) | (13.77) | (14.86) | (14.77) | (2.46) |
| EPS (basic, USD) | (12.87) | (25.68) | (16.8) | (7.82) | (3.46) | (0.41) |
| Cash (period-end) | 1.75 | 1.86 | 1.89 | 3.61 | 0.42 | 2.84 |
| Total assets (period-end) | 40.82 | 37.12 | 31.84 | 28.53 | 20.87 | 22.08 |
| Total liabilities (period-end) | 30.63 | 2.48 | 7.39 | 13.30 | 13.31 | 16.39 |

Source: Ainos Inc., VASRO

How we read it

To a sensor, a semiconductor fab and an emergency room are not so different — both are dense, high-sensitivity spaces where conditions shift by the minute and catching an anomaly early carries real value. Ainos's case is that the same Smell AI it will run in chip plants and robotics can turn toward a hospital corridor without reinventing the technology beneath it, and NTUH is where that case gets tested in the open, with a named institution rather than an anonymous site lending it weight.

For the equity, the read is straightforward: each new environment of this calibre widens the markets the platform can address and the data it can learn from — and it advances the bigger ambition management keeps returning to, of making Smell AI a new layer of environmental intelligence that sits across industry and healthcare alike. A leading hospital hosting the technology is a far stronger reference than any pilot. Still, we keep the discipline we have held throughout: this is a research program, not a purchase order, and the conversion into recurring SmellTech-as-a-Service revenue is the marker we are still watching for.

What to look for from here

- Results from the six-month study strong enough that the hospital wants to keep the system running, the natural next step from a trial to a lasting installation.
- The first signs that this becomes something Ainos can bring to other hospitals too, turning one leading-hospital win into a repeatable healthcare offering.

Our take

We read the NTUH program as a clear positive. Something we pointed to back in May has now happened, and it has happened well, in a live emergency room at one of Asia's leading hospitals. News like this moves two things that count for a company at this stage: how far the technology's reach now extends, and how much credibility stands behind it. Both moved firmly in the right direction.

Appendix

| P&L | | | | | | | |
|---|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| <i>(Amounts in USD millions, except per-share data)</i> | | | | | | | |
| Period Ending | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | 2026 31/03 |
| Revenue | 0.02 | 0.59 | 3.52 | 0.12 | 0.0200 | 0.12 | 0.00016 |
| Cost of sales | 0.01 | 0.18 | 2.11 | 0.38 | 0.0500 | 0.02 | 0.00076 |
| Gross profit | 0.01 | 0.41 | 1.41 | -0.25 | -0.0300 | 0.1029 | (0.00060) |
| Operating expenses: | | | | | | | |
| Research and development | 0.00 | 1.92 | 6.85 | 7.31 | 8.41 | 7.75 | 1.69 |
| Selling, general and administrative | 1.45 | 2.36 | 8.54 | 5.64 | 5.40 | 6.34 | 0.59 |
| Total operating expenses | 1.45 | 4.28 | 15.38 | 12.95 | 13.81 | 14.09 | 2.28 |
| Operating profit (loss) | -1.44 | -3.87 | -13.98 | -13.20 | -13.84 | -13.99 | (2.28) |
| Finance costs: | | | | | | | |
| Interest expense | -0.01 | -0.02 | -0.05 | -0.67 | -0.92 | -0.71 | (0.18) |
| Interest and investment income | 0.00 | — | — | — | — | 0.00 | 0.00 |
| Other non-operating expenses | 0.00 | 0.00 | 0.02 | 0.01 | 0.18 | -0.07 | 0.00072 |
| Net finance costs | -0.01 | -0.02 | -0.03 | -0.66 | -0.74 | -0.78 | (0.18) |
| Profit (loss) before unusual items | -1.45 | -3.89 | -14.01 | -13.86 | -14.59 | -14.77 | (2.46) |
| Other unusual items | — | — | — | 0.09 | -0.28 | 0.00 | 0.00 |
| Profit (loss) before tax | -1.45 | -3.89 | -14.01 | -14.05 | -14.86 | -14.77 | (2.46) |
| Income tax expense | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit (loss) for the period | -1.45 | -3.89 | -14.01 | -14.05 | -14.86 | -14.77 | (2.46) |
| Attributable to: | | | | | | | |
| Equity holders of the parent | -1.45 | -3.89 | -14.01 | -14.05 | -14.86 | -14.77 | (2.46) |
| Non-controlling interests | — | — | — | — | — | 0.00 | 0.00 |
| Per-share & share data | | | | | | | |
| Basic EPS - Continuing operations | -13.36 | -12.87 | -25.68 | 16.80 | -7.82 | -3.46 | (0.41) |
| Diluted EPS - Continuing operations | -13.36 | -12.87 | -25.68 | -17.13 | -7.82 | -3.46 | (0.41) |
| Dividend per share | — | — | — | — | — | 0.00 | 0.00 |
| Basic weighted average shares outstanding | 0.11 | 0.30 | 0.55 | 0.82 | 1.90 | 4.27 | 6.03 |
| Diluted weighted average shares outstanding | 0.11 | 0.30 | 0.55 | 0.82 | 1.90 | 4.27 | 6.03 |
| Supplementary operating metrics | | | | | | | |
| EBITDA | -1.43 | -1.82 | -9.14 | -8.33 | -9.04 | -9.21 | (1.11) |
| EBIT | -1.44 | -3.87 | -13.98 | -13.20 | -13.84 | -13.99 | (2.28) |

Source: Ainos, VASRO

Balance sheet
(Amounts in USD millions)

| Period Ending | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | 2026 31/03 |
|---|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| ASSETS | | | | | | | |
| Current assets | | | | | | | |
| Cash and cash equivalents | 0.02 | 1.75 | 1.86 | 1.89 | 3.89 | 0.42 | 2.84 |
| Accounts receivable | — | — | 0.20 | 0.00 | 0.00 | 0.00 | 0.000023 |
| Inventory | — | — | 0.60 | 0.17 | 0.14 | 0.30 | 0.32 |
| Other current assets | 0.05 | 0.47 | 0.20 | 0.42 | 0.30 | 0.43 | 0.36 |
| Total current assets | 0.08 | 2.22 | 2.86 | 2.47 | 4.34 | 1.14 | 3.52 |
| Non-current assets | | | | | | | |
| Property, plant and equipment | 0.00 | 1.19 | 1.38 | 0.88 | 0.56 | 0.34 | 0.29 |
| Intangible assets | 0.18 | 37.33 | 32.81 | 28.28 | 23.75 | 19.23 | 18.11 |
| Other non-current assets | — | 0.09 | 0.08 | 0.21 | 0.17 | 0.16 | 0.16 |
| Total non-current assets | 0.18 | 38.60 | 34.26 | 29.37 | 24.48 | 19.73 | 18.56 |
| TOTAL ASSETS | 0.26 | 40.82 | 37.12 | 31.84 | 28.82 | 20.87 | 22.08 |
| EQUITY AND LIABILITIES | | | | | | | |
| Current liabilities | | | | | | | |
| Short-term borrowings | 0.95 | 3.59 | 1.26 | — | 0.00 | 0.00 | 2.81 |
| Current portion of long-term debt | — | — | — | 0.04 | 3.00 | 0.00 | 2.00 |
| Accrued expenses | 0.15 | 1.00 | 1.21 | 1.18 | 0.85 | 0.73 | 1.18 |
| Contract liabilities | — | — | — | 0.11 | 0.11 | 0.35 | 0.35 |
| Other current liabilities | — | 26.00 | — | — | 0.00 | 0.00 | 0.00 |
| Total current liabilities | 1.10 | 30.59 | 2.47 | 1.34 | 3.95 | 1.08 | 6.35 |
| Non-current liabilities | | | | | | | |
| Long-term debt | — | — | — | 5.92 | 9.00 | 11.00 | 9.00 |
| Long-term leases | — | 0.03 | — | — | 0.00 | 0.00 | 0.00 |
| Other non-current liabilities | — | — | 0.01 | 0.14 | 0.35 | 1.23 | 1.04 |
| Total non-current liabilities | 0.00 | 0.04 | 0.01 | 6.05 | 9.35 | 12.23 | 10.04 |
| TOTAL LIABILITIES | 1.10 | 30.63 | 2.48 | 7.39 | 13.30 | 13.31 | 16.39 |
| Equity | | | | | | | |
| Common stock | 0.42 | 0.10 | 0.04 | 0.05 | 0.03 | 0.07 | 0.07 |
| Treasury stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.97 | (1.97) |
| Additional paid-in capital | 4.96 | 20.20 | 58.91 | 62.56 | 68.64 | 77.23 | 77.83 |
| Retained earnings (accumulated deficit) | (6.22) | (10.11) | (24.12) | (37.89) | -52.75 | -67.52 | (69.98) |
| Accumulated other comprehensive income (loss) | — | 0.01 | (0.20) | (0.27) | -0.41 | -0.25 | (0.26) |
| Total equity | (0.84) | 10.20 | 34.63 | 24.45 | 15.52 | 7.56 | 5.69 |
| TOTAL EQUITY AND LIABILITIES | 0.26 | 40.82 | 37.12 | 31.84 | 28.82 | 20.87 | 22.08 |

Source: Ainos, VASRO

Cash flow statement
(Amounts in USD millions)

| Period Ending | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | 2026 31/03 |
|---|---------------|---------------|---------------|---------------|---------------|---------------|-------------------|
| Cash flows from operating activities | | | | | | | |
| Net Income | (1.45) | (3.89) | (14.01) | (13.77) | (14.86) | -14.77 | (2.46) |
| Depreciation & Amortization, Total | 0.01 | 2.04 | 4.83 | 4.87 | 4.80 | 4.78 | 1.17 |
| Amortization of Deferred Charges, Total | — | — | — | 0.53 | 0.31 | 0.00 | 0.00 |
| Other Non-Cash Items, Total | 0.52 | 0.15 | 6.42 | 3.49 | 3.91 | 4.65 | 0.00 |
| Change in Net Operating Assets | 0.41 | 0.44 | (0.27) | 0.19 | 0.04 | 0.73 | 0.30 |
| Net cash from operating activities | (0.50) | (1.25) | (3.03) | (4.97) | (5.81) | (4.61) | (0.98) |
| Cash flows from investing activities | | | | | | | |
| Capital Expenditure | — | (0.14) | (0.63) | (0.09) | (0.02) | -0.03 | (0.0085) |
| Sale of Property, Plant, and Equipment | — | — | — | — | — | 0.00 | 0.00175 |
| Cash Acquisitions | — | — | — | — | — | 0.00 | 0.00 |
| Divestitures | — | — | — | — | — | 0.00 | 0.00 |
| Other Investing Activities | (0.01) | (0.04) | 0.00 | (0.01) | (0.10) | 0.03 | 0.00671 |
| Net cash from investing activities | (0.01) | (0.18) | (0.63) | (0.10) | (0.13) | (0.00) | (0.000079) |
| Cash flows from financing activities | | | | | | | |
| Total Debt Issued | 0.12 | 3.11 | 2.20 | 6.00 | 9.88 | 0.00 | 2.81 |
| Short Term Debt Issued, Total | 0.12 | 3.11 | 0.80 | — | — | 0.00 | 2.81 |
| Long-Term Debt Issued, Total | — | — | 1.40 | 6.00 | 9.88 | 0.00 | 0.00 |
| Total Debt Repaid | — | (0.02) | (0.13) | (0.69) | (1.75) | (1.00) | 0.00 |
| Short Term Debt Repaid, Total | — | 0.00 | (0.13) | (0.69) | (0.31) | 0.00 | 0.00 |
| Long-Term Debt Repaid, Total | — | (0.01) | — | — | (1.44) | (1.00) | 0.00 |
| Issuance of Common Stock | — | 0.06 | 1.78 | — | — | 2.01 | 0.60 |
| Other Financing Activities | — | — | — | (0.39) | (0.10) | 0.00 | 0.00 |
| Net cash from financing activities | 0.12 | 3.15 | 3.85 | 4.92 | 8.03 | 1.01 | 3.41 |
| Other adjustments | | | | | | | |
| Foreign Exchange Rate Adjustments | — | 0.01 | (0.08) | (0.10) | (0.08) | 0.13 | (0.007) |
| Miscellaneous Cash Flow Adjustments | — | — | — | — | — | 0.00 | 0.00 |
| Net increase/(decrease) in cash | (0.39) | 1.73 | 0.11 | -0.26 | 2.00 | (3.48) | 2.42 |
| Cash at beginning of period | 0.41 | 0.02 | 1.75 | 0.05 | 1.89 | 3.89 | 0.42 |
| Cash at end of period | 0.02 | 1.75 | 1.86 | 1.90 | 3.89 | 0.42 | 2.84 |

Source: Ainos, VASRO

Declaration of liability (disclaimer) and mandatory details pursuant to Section 85 Securities Trading Act (WpHG), the EU Market Abuse Regulation (EU Regulation No. 596/2014) and the Delegated Regulation 2016/958, including details of possible conflicts of interest (disclosures)

The following details recall such legal aspects and complete them as far as they refer to equity analyses with quarterly updates.

1. Creation and distribution

a) Responsibility for creation and distribution

VASRO GmbH (hereinafter referred to as „VASRO “)

Registered Office: Frankfurt am Main; Commercial Register No. HRB136283, Frankfurt am Main district court;

Managing Director: Dr. M-Javad Vaseghi

b) This document is intended primarily for use within the EEA and Switzerland. Distribution or use outside these jurisdictions may be subject to local laws; recipients are responsible for compliance.

c) Supervisory authority: Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Marie-Curie-Strasse 24-28, 60439 Frankfurt am Main.

2. Further mandatory details

a) First publication: 06/04/2026.

b) Publisher: Dr. Vaseghi, Javad, Mr. Roghani, Emad

c) Time conditions of expected updates: quarterly

d) Previous analyses: No analysis was published in the 12 months before publication of this analysis that contains a recommendation for a specific investment decision which contradicts this analysis.

e) The analysis was, if applicable, made available to the targeted company, to the extent that is legally permissible, before publication and was not amended thereafter.

f) All prices and price developments listed in the analysis are based on closing prices insofar as no contradictory details were provided about prices and price developments.

3. Remuneration Policy / Conflicts of Interest / Transparency

3.1 Remuneration Policy

The analysts of VASRO are compensated based on a fixed salary and/or project-based fees. Their remuneration is not linked to the performance of any financial instruments or the outcomes of the investment recommendations they provide, ensuring the impartiality and integrity of their analysis.

3.2 Conflict of Interest

VASRO operates independently of any investment banking or financial institution. As such, our analysts are free from conflicts of interest that could arise if there were a connection to investment banking operations or financial market activities. This independence reinforces the objectivity of any recommendation and analysis that might be provided by VASRO.

Neither VASRO nor an affiliated company, nor any person who contributes to the compilation of any study

a) has an involvement in the share capital of any targeted company of at least 5 percent;

b) is involved in the management of a syndicate within the five months preceding the issuance of the financial instruments of the targeted company in the context of a public tender;

c) manages financial instruments of any targeted company on a market by means of concluding purchase or sale agreements;

d) has, within the past twelve months, concluded an agreement regarding services in connection with investment banking business or received a service or performance promise from such agreement, with any targeted company which either itself or the financial instruments thereof, are the subject of a financial analysis;

e) is in possession of a net sales or purchase position which exceeds the threshold of 0.5% of the total issued share capital of any targeted company;

f) has concluded an agreement regarding the preparation of investment recommendations with any targeted company;

g) has other significant interests with regard any targeted company, for example common clients.

h) Independent, non-commissioned equity analysis; no issuer remuneration.

However, it is possible that shareholders, managers or employees of VASRO or its affiliated companies have a position of responsibility in the companies named in the analysis, e.g. as a member of the supervisory board.

3.3 Transparency

VASRO maintains a strict policy of transparency and disclosure, actively taking steps to avoid any real or perceived conflicts of interest in the provision of its services. Analysts are required to disclose any personal financial interests that may be seen as a conflict of interest with their duties to the company and its clients.

3.4. Disclosures of conflicts of interest

| Company | Disclosure (s) |
|------------|----------------|
| Ainos Inc. | h) |

4. Internal organizational and regulatory measures for the prevention or management of conflicts of interest

Employees of VASRO who are involved with the compilation and/or presentation of financial analyses are subject to the internal compliance regulations. The internal compliance regulations correspond to the legal provisions applicable in connection therewith, in particular the Market Abuse Regulation.

5. Sensitivity of the evaluation parameters

In case figures from profit and loss calculations, cash flow statements and balance sheets form the basis of a company evaluation, these are data-related estimates and therefore subject to risks and may change at any time without prior notice.

Regardless of the evaluation methods used, there are significant risks that a price goal/trend will not be achieved within the expected time frame. The risks include unforeseeable changes regarding competition pressure, demand for the products of a targeted company and the offer situation with respect to materials required for production as well as non-occurrence of the assumed development. Such deviations may be the result of changes relating to technology and changes relating to the economy, legal situation and exchange rates.

Furthermore, no claim is made that the above statement of evaluation methods and risk factors is complete.

6. Key sources of information

VASRO acquires the information upon which its services are based from generally recognized sources that are considered in principle to be reliable, in particular national and international media and information services (e.g. FactSet, Bloomberg etc.), the financial press (e.g. BörsenZeitung, FAZ, Handelsblatt, Wallstreet Journal, etc.), specialist press, published statistics and any other source from the internet considered as reliable as well as, if applicable, publications, details and information received from the targeted company that is the subject of the respective study.

However, it is not possible at reasonable expense to verify all this information. Therefore, VASRO cannot guarantee or ensure the accuracy, completeness or correctness of the information or opinions contained in any study or being the basis of any recommendation.

7. Summary of the basis for evaluation

Current and recognized evaluation methods (e.g. DCF method and Peer Group Analysis) are used for company analysis purposes.

The DCF method calculates the value of a targeted company based on the sum of the discounted cash flows, i.e. the cash value of the future cash flows of a targeted company. The value is therefore determined based on expected future cash flows and the applied discount rate.

In Peer Group Analysis, targeted companies listed on the stock exchange are evaluated by comparing ratios (e.g. price/profit ratio, Enterprise Value/turnover, Enterprise Value/EBITDA, Enterprise Value/EBIT). The comparability of the ratios is primarily determined with reference to the business activity and economic prospects.

8. Investment recommendation details

In case investment recommendations are made, they are to be defined as follows:

BUY: In our opinion, the stock will demonstrate an absolute price gain of at least 10 % in a 12-month period.

HOLD: In our opinion, the stock will not exceed or fall below an absolute price gain or loss of 10% in a 12-month period.

SELL: In our opinion, the stock will demonstrate an absolute price loss of at least 10 % in a 12-month period.

9. Recommendation History for the Last 12 Months:

| Date | Study | Stock Price at Publication (USD) | Change (%) |
|------------|---------|-------------------------------------|------------|
| 01/20/2026 | Initial | 1.93 | - |
| 02/02/2026 | Update | 2.00 | +3.6% |
| 02/18/2026 | Update | 1.33 | -33.5% |
| 02/24/2026 | Update | 1.45 | +9.0% |
| 04/01/2026 | Update | 1.39 | -4.1% |
| 04/16/2026 | Update | 1.61 | +15.8% |
| 05/19/2026 | Update | 1.66 | +3.1% |
| 06/04/2026 | Update | 2.20 | +32.5% |

10. Declaration of liability

For conducting its research activities, VASRO procures the actual details from the sources available that are generally deemed to be reliable. However, VASRO cannot make any claim regarding the accuracy and completeness of such information (cf. sec. 5 above).

The recommendations and/or prognoses made by VASRO based on these actual details constitute non-binding value judgments made at the time of compilation of the study and represent the opinion of the respective author. Subsequent changes thereof cannot be taken into account. Therefore, the opinions contained in any investment recommendation may be amended without notice at any time. All rights are reserved.

VASRO may therefore not be held liable for damages of any kind in relation to any incomplete or incorrect information being the basis of any analysis, report or recommendation whatsoever and VASRO may thus not be held liable for indirect and/or direct damages and/or consequential damages resulting therefrom.

In particular, VASRO may not be held liable for statements, plans or other details contained in any investment recommendation in relation to any company being investigated, its affiliated companies, strategies, market and/or competition situation, economic and/or legal framework conditions etc.

Although any investment recommendation or report is compiled using full diligence, errors or omissions cannot be excluded. VASRO, its shareholders and employees may therefore not be liable for the correctness or completeness of statements, assessments, recommendations or conclusions derived from the information contained in the respective analysis or report.

Furthermore, for any investment recommendation provided or any statement whatsoever made in the context of an existing contractual relationship, e.g. financial recommendation or a similar service, VASRO's liability shall be limited to gross negligence and intent. Should key details be omitted, VASRO shall be liable for ordinary negligence. The liability of VASRO shall be restricted to the amount of typical and predictable damages.



Ainos, Inc.

Unless expressly otherwise stated in the respective document, any study provided by VASRO does not constitute an offer or request to acquire shares. The information and recommendations in any document published by VASRO do not constitute individual investment advice and may therefore not be suitable, or may only be of limited suitability, for individual investors depending on the specific investment goals, the investment horizon or individual investment situation.

With the compilation and distribution of any study or report, VASRO is not engaged in an investment advisor or portfolio management capacity for any person. Any study or report delivered by VASRO may not replace the need for investment advice in any case.

The estimates, particularly prognoses and price expectations, may not be achieved. The work and all parts thereof are protected by copyright. All use outside the scope of copyright law is impermissible and prosecutable. This shall apply in particular to duplications, translations, microfilms, the saving and processing of the entire content or parts of the content on electronic media.

Upon acceptance of the equity analysis, the recipient confirms that the above restrictions are binding.